Kif18a inhibitor pipeline
Web7 mrt. 2024 · Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline. Financing led by founding investors Polaris Partners and ARCH Venture Partners … Web7 mrt. 2024 · Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline March 7, 2024 Financing led by founding investors Polaris Partners and ARCH Venture …
Kif18a inhibitor pipeline
Did you know?
Web15 apr. 2024 · When SDX-7320 was administered as a monotherapy at a dose of 8 mg/kg, it yielded a tumor growth inhibition rate (TGI) of 49%. Single-agent palbociclib, delivered at 20 mg/kg, elicited a TGI rate ... WebKinase-like protein 18A (KIF18A) is a mitotic kinesin motor protein that regulates chromosome positioning during cell division and is overexpressed in a subset of human cancers. 1-3. Preclinical studies of KIF18A gene inactivation suggest its function can be …
WebBTB-1 is a potent, selective and reversible mitotic motor protein Kif18A inhibitor with an IC50 of 1.69 μM. IC 50 & Target. IC50: 1.69 μM (Kif18A) [1] In Vitro. BTB-1 blocks the motility of Kif18A in a reversible manner. BTB-1 inhibits Kif18A in an adenosine triphosphate (ATP)-competitive but microtubule-uncompetitive manner and slows down ... Web9 sep. 2024 · Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline March 7, 2024 Financing led by founding investors Polaris Partners and ARCH Venture …
Web7 mrt. 2024 · Volastra Therapeutics announced Tuesday it has in-licensed Amgen’s Phase I candidate sovilnesib, a KIF18A inhibitor being studied for high-grade ovarian cancer, triple-negative breast cancer and other solid tumors. Concurrently, the New York-based … WebTwo known KIF18A inhibitors exist; however, their function is either limited (BTB-1) or the efficacy remains to be publicly validated (Amgen). In this thesis, a screening protocol involving fluorescent-based live cell imaging was formulated to test several small …
Web9 sep. 2024 · KIF18A inhibitor on track to enter the clinic in 2H 2024 NEW YORK, September 9, 2024 – Volastra Therapeutics , an oncology company focused on exploiting chromosomal instability (CIN), today announced new data from its lead program, a …
Web28 mei 2024 · TPS5600. Background: KIF18A is a mitotic kinesin motor protein that regulates chromosome positioning during cell division and is overexpressed in a subset of human cancers. TP53 mutant unstable aneuploid cancer cells with chromosomal … tips for taking nursing examsWeb29 sep. 2024 · September 29, 2024. By Christina Eng, Ph.D., VP, Head of Biology. Earlier this month at the FASEB Consequences of Aneuploidy conference, we shared the first preclinical data from our KIF18A inhibitor program targeting chromosomally unstable tumors. The data are highly encouraging, as they showed treatment with our KIF18A … tips for taking phentermineWeb9 sep. 2024 · KIF18A is a mitotic kinesin that regulates chromosome alignment during cell division. Leveraging its proprietary CINtech platform, Volastra discovered that CIN-high cancer cells are more dependent on chromosome alignment machinery like KIF18A and … tips for taking online college classesWeb20 feb. 2015 · Using BTB-1, the first identified Kif18A inhibitor, as a lead compound, we synthesized a collection of derivatives. We demonstrate that some of the synthesized derivatives potently inhibited the ATPase activity of Kif18A with a half maximal … tips for taking passport photoWeb8 mrt. 2024 · Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline Category: More News Published on Wednesday, 08 March 2024 08:50 Hits: 2551 Financing led by founding investors Polaris Partners and ARCH Venture Partners alongside Lilly. tips for taking night photosWeb7 mrt. 2024 · “We are excited to add sovilnesib to our growing pipeline of CIN-targeted therapeutics which includes our own KIF18A inhibitor, VLS-1488,” said Charles Hugh-Jones, Chief Executive Officer at Volastra. “Our focus is helping patients in critical need of new treatment options,” added Scott Drutman MD PhD, Chief Medical Officer. tips for taking ozempic for weight lossWeb2 jun. 2024 · Background: KIF18A is a kinesin assisting chromosome congression and alignment during mitosis. It is nonessential in normal, euploid cell division but essential for a subset of aneuploid cancer cells with high chromosomal instability (CIN-high). KIF18A … tips for taking out invisalign